Computational approach for binding prediction of SARS-CoV-2 with neutralizing antibodies
Coronavirus disease 2019 (COVID-19) caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide as a severe pandemic and caused enormous global health and economical damage. Since December 2019, more than 197 million cases have been reported, causing 4.2 milli...
Main Authors: | Daria Beshnova, Yan Fang, Mingjian Du, Yehui Sun, Fenghe Du, Jianfeng Ye, Zhijian James Chen, Bo Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Computational and Structural Biotechnology Journal |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2001037022001556 |
Similar Items
-
Real-world clinical effectiveness of Tixagevimab/Cilgavimab and Regdanvimab monoclonal antibodies for COVID-19 treatment in Omicron variant-dominant period
by: Daria S. Fomina, et al.
Published: (2023-10-01) -
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased in vitro activity: a nationwide real-world multicenter cohort study
by: Haein Kim, et al.
Published: (2023-05-01) -
Efficacy and safety of regdanvimab in patients with mild/moderate COVID-19 and high risk of progression of the disease: a retrospective study in a short-term stay unit
by: Ulyana A. Markina, et al.
Published: (2022-06-01) -
The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
by: Ganghee Chae, et al.
Published: (2022-03-01) -
Effectiveness of regdanvimab on mortality in COVID-19 infected patients on hemodialysis
by: Youn Kyung Kee, et al.
Published: (2024-01-01)